Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SASHI K MAKAM

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1861494908
CMS profile
356994
Location
NEW WINDSOR, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$3,299.53

177 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,249.53 175
Education $50.00 2

By paying entity

PY2023 · entire year · sorted by reported total

Page 4 of 4; records 151–177 of 177 matching records. This page contains 27 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SASHI K MAKAM

NPI 1861494908 · CMS profile ID 356994

Allopathic & Osteopathic Physicians / Internal Medicine

NEW WINDSOR, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–177 of 177 matching records. This page contains 27 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1861494908?year=2023&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SASHI K MAKAM, NPI 1861494908, CMS profile ID 356994. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–177 of 177 matching records. This page contains 27 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1861494908?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). SASHI K MAKAM, NPI 1861494908, CMS profile ID 356994. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–177 of 177 matching records. This page contains 27 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1861494908?year=2023&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
SASHI K MAKAM, NPI 1861494908, CMS profile ID 356994, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–177 of 177 matching records. This page contains 27 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1861494908?year=2023&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

177 matching records · $3,299.53 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 177 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–177 of 177.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $16.3503/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020674307 CMS
GlaxoSmithKline, LLC. $18.8903/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002217675 CMS
Lilly USA, LLC $12.5903/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032182857 CMS
ABBVIE INC. $16.6102/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997821009 CMS
ABBVIE INC. $33.1802/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997821011 CMS
Novo Nordisk Inc $11.0502/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000893891 CMS
Lilly USA, LLC $17.0202/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032387477 CMS
AstraZeneca Pharmaceuticals LP $35.0002/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025003147 CMS
Novo Nordisk Inc $14.2402/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000894047 CMS
Novartis Pharmaceuticals Corporation $20.2802/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992943725 CMS
PFIZER INC. $8.6702/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049221543 CMS
Novo Nordisk Inc $6.9602/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000893725 CMS
Amgen Inc. $14.8602/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020674305 CMS
Exact Sciences Corporation $19.1602/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1026582515 CMS
GlaxoSmithKline, LLC. $9.2202/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002215139 CMS
AstraZeneca Pharmaceuticals LP $18.7902/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1025060691 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $13.1501/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997000559 CMS
IDORSIA PHARMACEUTICALS US INC $16.6801/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038224199 CMS
Lilly USA, LLC $5.9801/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032207661 CMS
Lilly USA, LLC $2.1601/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032207667 CMS
Novartis Pharmaceuticals Corporation $19.8101/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 992943729 CMS
ABBVIE INC. $2.3701/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997821007 CMS
GlaxoSmithKline, LLC. $13.7101/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002217581 CMS
Novo Nordisk Inc $9.7901/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000893845 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $23.9301/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057203287 CMS
Dexcom, Inc. $17.7801/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054856923 CMS
ABBVIE INC. $27.3001/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997821005 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,176.53 204
PY2020 $2,619.73 151
PY2021 $4,108.15 204
PY2022 $3,791.52 204
PY2023 $3,299.53 177
PY2024 $3,644.73 178
PY2025 $6,977.79 186

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,597,587.44 86
PY2024 Recipient $4,915.80 2
PY2024 Principal investigator $1,024,395.34 96
PY2023 Recipient $8,918.76 3
PY2023 Principal investigator $1,226,252.03 124
PY2022 Principal investigator $219,103.85 166
PY2021 Principal investigator $508,775.89 397
PY2020 Principal investigator $863,832.62 334
PY2019 Principal investigator $698,327.86 243

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

86 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $1,102.20 12/31/2025 Non-covered Recipient Entity
Mid Hudson Medical Research
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-na ve Adults 18 to 64 years of Age With Increased Risk for Pneumococcal Disease No dispute reported 06/30/2026 1232934094
Principal investigator 1 PFIZER INC. $905.85 12/31/2025 Non-covered Recipient Entity
Mid Hudson Medical Research PLLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228745730
Principal investigator 1 Genentech, Inc. $13,925.05 12/24/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211625444
Principal investigator 1 GlaxoSmithKline, LLC. $500.18 12/24/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192154960
Principal investigator 1 GlaxoSmithKline, LLC. $828.90 12/24/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192158118
Principal investigator 1 GlaxoSmithKline, LLC. $2,408.07 12/24/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192158123
Principal investigator 1 PFIZER INC. $10,345.73 12/17/2025 Non-covered Recipient Entity
Mid Hudson Medical Research PLLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228723746
Principal investigator 1 PFIZER INC. $42,956.33 12/16/2025 Non-covered Recipient Entity
Mid Hudson Medical Research PLLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228731949
Principal investigator 1 GlaxoSmithKline, LLC. $4,315.96 12/11/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192154979
Principal investigator 1 Genentech, Inc. $1,650.00 12/03/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211625448
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,958.87 12/01/2025 Non-covered Recipient Entity
Mid Hudson Medical Research PLLC
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508610
Principal investigator 1 PFIZER INC. $7,189.92 11/27/2025 Non-covered Recipient Entity
Mid Hudson Medical Research PLLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228739311
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $481.65 11/20/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244043770
Principal investigator 1 Alnylam Pharmaceuticals Inc. $12,500.00 11/05/2025 Non-covered Recipient Entity
Mid Hudson Medical Research PLLC
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508613
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,000.00 11/05/2025 Non-covered Recipient Entity
Mid Hudson Medical Research PLLC
A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease No dispute reported 06/30/2026 1215508617
Principal investigator 1 Genentech, Inc. $2,000.00 11/05/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211625439
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,950.00 11/03/2025 Non-covered Recipient Entity
Mid Hudson Medical Research, Pllc
A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease No dispute reported 06/30/2026 1235995701
Principal investigator 1 GlaxoSmithKline, LLC. $6,631.20 10/23/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192154957
Principal investigator 1 GlaxoSmithKline, LLC. $6,250.00 10/22/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192158037
Principal investigator 1 Celgene Corporation $14,500.00 10/15/2025 Non-covered Recipient Entity
Mid Hudson Medical Research, Pllc
A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease No dispute reported 06/30/2026 1222305246
Principal investigator 1 GlaxoSmithKline, LLC. $1,200.00 10/15/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192158024
Principal investigator 1 SANOFI US SERVICES INC. $15,967.00 10/14/2025 Non-covered Recipient Entity
Mid Hudson Medical Research
A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype No dispute reported 06/30/2026 1226137155
Principal investigator 1 GlaxoSmithKline, LLC. $2,925.00 10/10/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192158029
Principal investigator 1 GlaxoSmithKline, LLC. $10,000.00 10/10/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192158033
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $761.00 10/09/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244043768
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,615.19 09/24/2025 Non-covered Recipient Entity
Mid Hudson Medical Research, Pllc
A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agitation in Participants with Alzheimer's Disease No dispute reported 06/30/2026 1235995697
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,852.69 09/05/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH, PLLC
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1185551235
Principal investigator 1 Verona Pharma, Inc. $10,000.00 09/03/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RSRCH. PLLC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891671
Principal investigator 1 Verona Pharma, Inc. $1,852.00 09/03/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RSRCH. PLLC
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891673
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,211.95 08/19/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244043766
Principal investigator 1 PFIZER INC. $1,837.36 08/13/2025 Non-covered Recipient Entity
Mid Hudson Medical Research PLLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228768001
Principal investigator 1 PFIZER INC. $762.76 08/06/2025 Non-covered Recipient Entity
Mid Hudson Medical Research PLLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228760606
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 08/05/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244043904
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $481.65 07/24/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244043764
Principal investigator 1 PFIZER INC. $1,287.23 07/23/2025 Non-covered Recipient Entity
Mid Hudson Medical Research PLLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228781761
Principal investigator 1 PFIZER INC. $9,060.59 07/11/2025 Non-covered Recipient Entity
Mid Hudson Medical Research PLLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228789929
Principal investigator 1 Genentech, Inc. $6,300.00 07/02/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211625436
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $29,675.91 06/25/2025 Non-covered Recipient Entity
Mid Hudson Medical Research, Pllc
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Agitation Associated with Alzheimers Disease No dispute reported 06/30/2026 1235995699
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,820.75 06/24/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244043762
Principal investigator 1 PFIZER INC. $26,538.48 06/21/2025 Non-covered Recipient Entity
Mid Hudson Medical Research PLLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228793616
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $68.20 06/19/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244043902
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,600.00 06/11/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH, PLLC
A Phase II, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure in Participants with Atherosclerotic Cardiovascular Disease or Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol No dispute reported 06/30/2026 1185551243
Principal investigator 1 PFIZER INC. $38,096.43 06/06/2025 Non-covered Recipient Entity
Mid Hudson Medical Research PLLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228792389
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,250.00 06/05/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244043760
Principal investigator 1 Genentech, Inc. $900.00 06/04/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211625427
Principal investigator 1 GlaxoSmithKline, LLC. $2,251.12 05/22/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192158101
Principal investigator 1 Genentech, Inc. $1,800.00 05/09/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211625423
Principal investigator 1 PFIZER INC. $66,156.20 04/29/2025 Non-covered Recipient Entity
Mid Hudson Medical Research PLLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228796563
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,193.29 04/23/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH, PLLC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1190313327
Principal investigator 1 GlaxoSmithKline, LLC. $1,657.80 04/17/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192154975
Principal investigator 1 Genentech, Inc. $900.00 04/11/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211625432
Principal investigator 1 PFIZER INC. $58,181.80 04/10/2025 Non-covered Recipient Entity
Mid Hudson Medical Research PLLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228780252
Principal investigator 1 PFIZER INC. $9,788.88 04/01/2025 Non-covered Recipient Entity
Mid Hudson Medical Research PLLC
A PHASE 3 MULTICENTER PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE EFFICACY SAFETY TOLERABILITY IMMUNOGENICITY AND LOT CONSISTENCY OF A 6VALENT OSPABASED LYME DISEASE VACCINE IN HEALTHY PARTICIPANTS 5 YEARS OF AGE No dispute reported 06/30/2026 1228791006
Principal investigator 1 Genentech, Inc. $1,800.00 03/21/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211625409
Principal investigator 1 Otsuka Pharmaceutical Development & Commercialization, Inc. $173.75 03/21/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AVP-786 (DEUDEXTROMETHORPHAN HYDROBROMIDE [D6-DM]/QUINIDINE SULFATE [Q]) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA OF THE ALZHEIMERS TYPE No dispute reported 06/30/2026 1225335721
Principal investigator 1 GlaxoSmithKline, LLC. $12,189.51 03/20/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192158115
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,738.45 03/20/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244043758
Principal investigator 1 AstraZeneca UK Limited $88,966.20 03/12/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH, PLLC
A Phase II, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure in Participants with Atherosclerotic Cardiovascular Disease or Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol No dispute reported 06/30/2026 1185551245
Principal investigator 1 Genentech, Inc. $2,380.00 03/05/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211625421
Principal investigator 1 Genentech, Inc. $2,380.00 02/21/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211625390
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 02/21/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244043900
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 02/20/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192154965
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 02/20/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192154970
Principal investigator 1 GlaxoSmithKline, LLC. $1,550.00 02/20/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192158020
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 02/20/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192158096
Principal investigator 1 GlaxoSmithKline, LLC. $675.00 02/20/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192158127
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 02/20/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192158131
Principal investigator 1 Genentech, Inc. $1,800.00 02/12/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211625397
Principal investigator 1 Genentech, Inc. $8,160.00 02/05/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211625413
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,848.85 01/31/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH, PLLC
A Phase 2 Randomized Doubleblind Placebo-controlled Doseranging Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of AZD0780 in Participants with Dyslipidemi No dispute reported 06/30/2026 1185551237
Principal investigator 1 Eli Lilly and Company $1,033.03 01/31/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY No dispute reported 06/30/2026 1187884958
Principal investigator 1 Eli Lilly and Company $535.00 01/31/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) No dispute reported 06/30/2026 1187885506
Principal investigator 1 Eli Lilly and Company $1,708.45 01/31/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187886752
Principal investigator 1 GlaxoSmithKline, LLC. $12,384.59 01/30/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192158105
Principal investigator 1 GlaxoSmithKline, LLC. $8,361.92 01/30/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192158111
Principal investigator 1 AstraZeneca Pharmaceuticals LP $60,982.50 01/29/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH, PLLC
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185551239
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,629.27 01/29/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH, PLLC
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) No dispute reported 06/30/2026 1185551247
Principal investigator 1 Eli Lilly and Company $22,975.00 01/28/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187884642
Principal investigator 1 Eli Lilly and Company $45,862.68 01/27/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A STUDY OF RETATRUTIDE (LY3437943) IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE OBESITY OR OVERWEIGHT (TRIUMPH-2) No dispute reported 06/30/2026 1187886726
Principal investigator 1 Genentech, Inc. $640.00 01/22/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211625404
Principal investigator 1 Genentech, Inc. $320.00 01/17/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211625401
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,738.45 01/16/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244043756
Principal investigator 1 Genentech, Inc. $1,020.00 01/14/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211625394
Principal investigator 1 Genentech, Inc. $1,460.00 01/13/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211625418
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,375.59 01/08/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH, PLLC
A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of AZD4831, for 12-24 Weeks, in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1185551241
Principal investigator 1 Eli Lilly and Company $836,983.21 01/07/2025 Non-covered Recipient Entity
MID HUDSON MEDICAL RESEARCH PLLC
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY No dispute reported 06/30/2026 1187884268